X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs DIVIS LABORATORIES - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS DIVIS LABORATORIES IPCA LABS/
DIVIS LABORATORIES
 
P/E (TTM) x 35.6 31.9 111.7% View Chart
P/BV x 3.4 5.2 65.3% View Chart
Dividend Yield % 0.2 1.0 15.9%  

Financials

 IPCA LABS   DIVIS LABORATORIES
EQUITY SHARE DATA
    IPCA LABS
Mar-17
DIVIS LABORATORIES
Mar-17
IPCA LABS/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs6431,222 52.6%   
Low Rs503784 64.1%   
Sales per share (Unadj.) Rs254.4153.1 166.2%  
Earnings per share (Unadj.) Rs16.139.9 40.2%  
Cash flow per share (Unadj.) Rs29.844.6 66.8%  
Dividends per share (Unadj.) Rs1.0010.00 10.0%  
Dividend yield (eoy) %0.21.0 17.5%  
Book value per share (Unadj.) Rs194.6201.8 96.4%  
Shares outstanding (eoy) m126.20265.47 47.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.36.6 34.4%   
Avg P/E ratio x35.725.1 142.0%  
P/CF ratio (eoy) x19.222.5 85.5%  
Price / Book Value ratio x2.95.0 59.2%  
Dividend payout %6.225.0 24.9%   
Avg Mkt Cap Rs m72,300266,266 27.2%   
No. of employees `00013.39.7 136.7%   
Total wages/salary Rs m6,9604,687 148.5%   
Avg. sales/employee Rs Th2,413.54,175.0 57.8%   
Avg. wages/employee Rs Th523.2481.5 108.7%   
Avg. net profit/employee Rs Th152.41,089.3 14.0%   
INCOME DATA
Net Sales Rs m32,10640,643 79.0%  
Other income Rs m226749 30.1%   
Total revenues Rs m32,33241,392 78.1%   
Gross profit Rs m4,44814,460 30.8%  
Depreciation Rs m1,7301,233 140.2%   
Interest Rs m24123 1,065.5%   
Profit before tax Rs m2,70313,953 19.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6753,349 20.2%   
Profit after tax Rs m2,02810,604 19.1%  
Gross profit margin %13.935.6 38.9%  
Effective tax rate %25.024.0 104.1%   
Net profit margin %6.326.1 24.2%  
BALANCE SHEET DATA
Current assets Rs m17,34040,105 43.2%   
Current liabilities Rs m9,5596,595 145.0%   
Net working cap to sales %24.282.5 29.4%  
Current ratio x1.86.1 29.8%  
Inventory Days Days100119 84.6%  
Debtors Days Days5781 70.5%  
Net fixed assets Rs m20,77919,995 103.9%   
Share capital Rs m252531 47.5%   
"Free" reserves Rs m24,49953,043 46.2%   
Net worth Rs m24,55353,574 45.8%   
Long term debt Rs m3,5170-   
Total assets Rs m39,59561,585 64.3%  
Interest coverage x12.2618.4 2.0%   
Debt to equity ratio x0.10-  
Sales to assets ratio x0.80.7 122.9%   
Return on assets %5.717.3 33.2%  
Return on equity %8.319.8 41.7%  
Return on capital %10.526.1 40.2%  
Exports to sales %48.60-   
Imports to sales %14.225.2 56.4%   
Exports (fob) Rs m15,617NA-   
Imports (cif) Rs m4,57110,259 44.6%   
Fx inflow Rs m15,61735,384 44.1%   
Fx outflow Rs m5,82810,399 56.0%   
Net fx Rs m9,79024,985 39.2%   
CASH FLOW
From Operations Rs m2,76411,493 24.1%  
From Investments Rs m-1,432-11,372 12.6%  
From Financial Activity Rs m-1,591-93 1,709.2%  
Net Cashflow Rs m-25928 -911.3%  

Share Holding

Indian Promoters % 45.9 52.0 88.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 11.8 96.6%  
FIIs % 25.3 19.0 133.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 17.2 101.2%  
Shareholders   36,892 31,796 116.0%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   DR. DATSONS LABS  STRIDES SHASUN LTD  TTK HEALTHCARE  JUBILANT LIFE SCIENCES  BIOCON LTD  

Compare IPCA LABS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day up 260 Points; Pharma Stocks Top Gainers(Closing)

After opening the day in red, share markets in India witnessed positive trading activity throughout the day and ended the day on a positive note.

Related Views on News

IPCA LABS Announces Quarterly Results (4QFY18); Net Profit Up 15.6%

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, IPCA LABS has posted a net profit of Rs 513 m (up 15.6% YoY). Sales on the other hand came in at Rs 8 bn (up 17.6% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY18); Net Profit Up 0.9%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.9% YoY). Sales on the other hand came in at Rs 11 bn (up 2.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Jun 22, 2018 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS 8-QTR ANALYSIS

COMPARE IPCA LABS WITH

MARKET STATS